Bioxodes topped a list of six biotech companies whose medicines are derived from animals in an article in Labiotech.eu, Europe’s leading biotech news website. “Some of the most exciting therapies in the future could come from animals,” the article concluded. At Bioxodes, we couldn’t agree more! The saliva of the tick contains proteins which Bioxodes uses in its BIOX-101 therapy for hemorrhagic stroke, an often deadly condition. BIOX-101 has anti-clotting and anti-inflammatory properties, without causing further bleeding. The article also listed Celtic Biotech Ltd, which uses the venom of the rattlesnake to battle cancer, and Soricimed Biopharma Inc., whose cancer drugs are derived from the saliva of the northern short-tailed shrew, a venomous mammal from Northern America. Bioxodes is enrolling the first 16 intracerebral hemorrhagic stroke (ICH) patients in a Phase 2a study with BIOX-101, and expects interim results in the first quarter of 2025. The study is taking place across 10 stroke centres in Belgium, and is led by Prof Robin Lemmens, a world-leading stroke authority, and head of clinic at the University Hospital Leuven, UZ Leuven. Link to the full article: https://www.labiotech.eu/best-biotech/biomimicry-companies-drug-development/